The FDA have been describing some of the issues that they are seeing with the SEND packages for safety pharmacology studies.
What is the big deal with requiring juvenile studies in SEND v3.1/3.1.1?
There are advantages to aligning our nonclinical lexicons with the SEND CT terms, but there are potential pitfalls and things to consider too.
Dr Brenda Finney shares her thoughts on the use of SEND for data exchange in data warehouses like our Centrus platform which is built on the ToxHub database.
In the world of SEND, there are main topics that keep reoccurring. Subjects that need revisiting partly with fresh impetus but mainly because these are the things that keep cropping up and become the main...
In this post we discuss the submission implications of the publication of the new implementation guides for SENDIG-Genetox v1.0 and SENDIG-DART v1.2.
